PTC Therapeutics (PTCT) Buy Rating Maintained at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)
February 23, 2015 12:28 PM ESTPTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.
$BMRN is interested in buying $PTCT? Thats hard to believe.
— Adam Feuerstein (@adamfeuerstein) February 23, 2015... More
UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters
February 23, 2015 12:03 PM EST(Updated - February 23, 2015 12:43 PM EST)
PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.
According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More
